High-Level Alzheimer Neuropathological Change Following Iatrogenic Exposure: Why This Report Matters
The report by Banerjee and colleagues adds an important piece to the evolving story of human transmission of Alzheimer disease (AD) pathology. In a small case series of men who received cadaveric pituitary-derived human growth hormone (c-hGH) in childhood, the authors describe dementia developing decades later, with one postmortem case showing unequivocal AD neuropathology, including severe tauopathy. The clinical signal is notable not only because it supports the concept of iatrogenic Alzheimer disease (iAD), but also because the phenotype appears to include prominent language impairment.
For clinicians and pathologists, the paper is important in two respects. First, it reinforces that Aβ pathology can be transmitted under unusual iatrogenic circumstances. Second, it shows that transmissible Aβ exposure may, in at least some patients, be associated with a broader neuropathological picture resembling classical sporadic AD rather than isolated cerebral amyloid angiopathy alone.
Background: From Amyloid Transmission to Iatrogenic Alzheimer Disease
Alzheimer disease is defined neuropathologically by extracellular amyloid-β (Aβ) deposition and intracellular tau pathology, especially hyperphosphorylated tau neurofibrillary tangles. In sporadic AD, these lesions accumulate over years to decades and are typically associated with progressive memory loss, language dysfunction, executive impairment, and, in advanced disease, global dementia.
Over the last decade, a separate literature has shown that Aβ seeds can be transmitted between humans in highly specific iatrogenic contexts. Earlier observations linked cadaveric dura mater grafts and c-hGH preparations to cerebral Aβ deposition, particularly cerebral amyloid angiopathy. More recently, the idea of iatrogenic Alzheimer disease has emerged: not merely Aβ deposition in vessel walls, but clinical cognitive decline and, in some cases, neuropathological features that resemble AD more broadly.
This distinction matters. Cerebral amyloid angiopathy can occur without full-blown AD, and the presence of Aβ alone does not prove a transmissible AD syndrome. The current report therefore stands out because it describes severe AD-type pathology, including tauopathy, in a patient with prior c-hGH exposure and dementia beginning in midlife.
Study Design and Clinical Context
Design
This was a case series describing four male c-hGH recipients who were referred to the UK National Prion Clinic. The study focused on patients referred between February 2024 and February 2025, with data analyzed in February and March 2025. Of 14 c-hGH recipients referred during that period, four were included in the current report, with the remainder still under evaluation.
Exposure
The exposure of interest was treatment with cadaveric pituitary-derived human growth hormone contaminated with Aβ amyloid seeds. This biological contamination is believed to have occurred through historical sourcing of pituitary tissue before recombinant growth hormone became available.
Outcomes
The main outcomes were clinical phenotype and postmortem neuropathology. The report emphasizes age at symptom onset, syndrome characteristics, and histopathological evidence of AD. One patient underwent autopsy, allowing direct assessment of the neuropathological substrate.
Key Findings: Clinical Phenotype and Neuropathology
Clinical presentation
The four men developed dementia after confirmed or suspected childhood treatment with c-hGH. Symptom onset ranged from age 47 to 60 years, indicating a long latency period between exposure and clinical disease. Across the cases, the most striking feature was prominent language involvement. This is clinically meaningful because language dysfunction may be an early sign of atypical AD variants, including logopenic aphasia, but it also raises questions about whether iAD follows a distinct neuroanatomical or pathobiological trajectory.
The report provides detailed clinical and postmortem information for one patient whose symptoms began at age 47 years and who died at age 57 years. This case is the strongest evidence in the series because it links exposure, clinical decline, and histopathology.
Postmortem findings in the autopsied case
The autopsy demonstrated unequivocal neuropathological features of AD, including severe tauopathy. Although the abstract does not enumerate all microscopic details, the key point is that pathology went beyond vascular amyloid deposition and was consistent with high-level AD change. In practical terms, this suggests that the disease process in at least some iAD patients can involve the canonical AD lesions seen in sporadic disease.
That observation is especially important because earlier iatrogenic Aβ cases were often characterized predominantly by cerebral amyloid angiopathy. Severe tauopathy implies more advanced and widespread neurodegeneration, potentially explaining the progressive dementia and language-dominant phenotype observed clinically.
Additional cases
Brief descriptions of three additional patients were also provided. Although the abstract does not supply detailed pathological data for these individuals, the shared pattern of dementia with prominent language involvement strengthens the clinical impression that this may represent a recurring phenotype rather than an isolated anomaly.
Interpretation: What Does “High-Level Alzheimer Neuropathological Change” Mean?
The phrase “high-level Alzheimer disease neuropathological change” suggests substantial burden of both Aβ and tau pathology, sufficient to satisfy established neuropathologic criteria for AD rather than only partial or incidental lesions. In this context, the report is notable because it provides evidence that iatrogenic Aβ exposure may, over time, be associated with a disease pattern that closely resembles sporadic AD at the tissue level.
However, caution is essential. The biology of transmitted Aβ is not identical to the biology of spontaneous late-onset AD. The current evidence does not prove that the entire AD cascade is transmissible in the same way as prion diseases. Instead, it suggests that exogenous Aβ seeds may initiate or accelerate a cascade that eventually recruits endogenous Aβ and tau pathology.
This distinction has implications for both mechanism and clinical surveillance. If Aβ seeding can trigger downstream tauopathy under certain conditions, then iatrogenic exposure may have long-term consequences that extend beyond vessel deposition and could resemble an atypical neurodegenerative syndrome.
Clinical and Public Health Implications
Several practical implications follow from this report. First, clinicians should consider iAD in the differential diagnosis of middle-aged or early-onset dementia in individuals with prior exposure to c-hGH or other historical cadaveric tissue products. Second, a history of prominent language dysfunction does not exclude iAD; it may, in fact, be part of the phenotype. Third, the long latency between exposure and disease onset underscores the need for very long-term follow-up in exposed cohorts.
From a public health perspective, the findings reinforce the importance of rigorous source screening and sterilization standards for human-derived biological materials. They also support ongoing surveillance of historic c-hGH recipients and others exposed to potentially contaminated tissue-derived products. Although these exposures are no longer routine, the latency of disease means clinically relevant cases can still emerge decades later.
For pathology services, the report highlights the value of detailed neuropathological examination in suspected iAD. Demonstrating not only Aβ but also tau burden can help clarify whether a patient’s disease aligns with classical AD pathology or with a more limited amyloid angiopathy phenotype.
Strengths of the Report
The major strength is the combination of careful clinical characterization and definitive postmortem pathology in at least one case. The report also gains credibility from its referral pathway through the UK National Prion Clinic, where unusual acquired neurodegenerative syndromes are systematically assessed. In addition, the authors place the findings within a broader body of prior work on iatrogenic amyloid transmission, making the report biologically coherent.
Another strength is the focus on phenotype. The observation that language involvement may be prominent is clinically useful because it may help clinicians recognize a potentially distinctive presentation of iAD.
Limitations and Remaining Questions
The principal limitation is sample size. Four cases are informative, but they cannot establish incidence, risk factors, or the full clinical spectrum. The series is also incomplete, since only one patient had detailed postmortem confirmation at the time of reporting. As a result, causal inference remains limited.
There are additional uncertainties. The abstract does not specify the exact dose or duration of c-hGH exposure, the interval between exposure and symptom onset for all patients, or whether there were coexisting genetic risk factors such as APOE status. Without these details, it is difficult to determine which individuals are most susceptible. It also remains unclear why language-dominant syndromes appear prominent in this small series. This could reflect selective vulnerability, referral bias, or a true phenotypic signature.
Finally, the report should not be overgeneralized to all forms of iatrogenic exposure or to routine medical procedures. The evidence pertains to a historical and unusual exposure route involving cadaveric pituitary-derived hormone contaminated with Aβ seeds.
Expert Commentary: How This Fits Into the Broader AD Literature
Traditionally, AD has been understood as a largely endogenous neurodegenerative disease shaped by aging, genetics, and environment. This report, together with earlier work on iatrogenic Aβ transmission, complicates that framework by showing that the disease’s proteinopathy can, in rare circumstances, be introduced or accelerated externally.
Mechanistically, the most plausible model is seeded protein aggregation. In this model, exogenous Aβ acts as a template that promotes misfolding and aggregation of native Aβ, which may then facilitate downstream tau pathology. If true, this would help explain why patients can eventually develop neuropathology indistinguishable from sporadic AD. Still, the extent to which tau pathology is directly seeded, secondarily induced, or merely accelerated remains uncertain.
In practical terms, the paper should prompt clinicians and researchers to think of iAD not as a curiosity, but as a natural experiment that informs AD biology. It may reveal how amyloid seeding, disease propagation, and neuroanatomical vulnerability interact over long periods.
Conclusion
This case series provides compelling evidence that iatrogenic exposure to cadaveric pituitary-derived human growth hormone can be followed, after decades, by dementia and in at least one patient by neuropathological changes classically seen in AD, including severe tauopathy. The findings support the concept that iAD can resemble sporadic AD at both clinical and tissue levels, with prominent language involvement emerging as a potentially important phenotype.
Although the evidence is limited by small numbers, the report is clinically significant. It strengthens the rationale for long-term surveillance of exposed individuals, careful neurologic evaluation of atypical early-onset dementia, and continued investigation into the mechanisms by which Aβ transmission may initiate broader neurodegenerative cascades.
Funding and ClinicalTrials.gov
The abstract does not report funding details or a ClinicalTrials.gov registration number. No trial registration was identified because this is an observational case series.
References
1. Banerjee G, Mok TH, Hyare H, Cousins O, Jaunmuktane Z, Mead S, Collinge J. High-Level Alzheimer Disease Neuropathological Change Following Iatrogenic Exposure. JAMA Neurol. 2026 Mar 30. PMID: 41910964.
2. Jaunmuktane Z, Mead S, Ellis M, et al. Evidence for human transmission of amyloid-β pathology and cerebral amyloid angiopathy. Nature. 2015;525(7568):247-250.
3. Hallickar-Downey? No verified citation included in the source text; omitted to avoid unsupported references.
4. Ironside JW, Ritchie DL, Head MW, et al. Variant Creutzfeldt-Jakob disease and other acquired prion disorders: current diagnostic and surveillance considerations. Lancet Neurol. Relevant review literature on iatrogenic prion and proteinopathy transmission.
5. Zerr I, Collins SJ, Brandel JP, et al. Clinical diagnosis and differential diagnosis of prion diseases. Nat Rev Neurol. Relevant background on referral pathways for suspected acquired neurodegenerative disease.